LM11A-31 HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555874

CAS#: 1243259-19-9 (HCl)

Description: LM11A-31 is a small-molecule p75NTR modulator and proNGF antagonist, in preventing diabetes-induced BRB breakdown. Targeting p75NTR signalling using LM11A-31, an orally bioavailable receptor modulator, may offer an effective, safe and non-invasive therapeutic strategy for treating macular oedema, a major cause of blindness in diabetes.

Chemical Structure

LM11A-31 HCl
CAS# 1243259-19-9 (HCl)

Theoretical Analysis

MedKoo Cat#: 555874
Name: LM11A-31 HCl
CAS#: 1243259-19-9 (HCl)
Chemical Formula: C12H27Cl2N3O2
Exact Mass:
Molecular Weight: 316.267
Elemental Analysis: C, 45.57; H, 8.61; Cl, 22.42; N, 13.29; O, 10.12

Size Price Shipping out time Quantity
10mg USD 90 Same day
25mg USD 150 Same day
50mg USD 250 Same day
100mg USD 450 Same day
200mg USD 750 Same day
500mg USD 1650 Same day
1g USD 2850 Same day
2g USD 4950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-02-24. Prices are subject to change without notice.

LM11A-31 HCl is in stock

Related CAS #: 1243259-19-9 (HCl)   102562-74-3 (free base)    

Synonym: LM11A-31 HCl; LM11A-31 hydrochloride; LM11A-31; LM11A 31; LM11A31; LM 11A-31; LM 11A31; LM-11A-31;

IUPAC/Chemical Name: (2S,3S)-2-amino-3-methyl-N-[2-(4-morpholinyl)ethyl]-pentanamide, dihydrochloride


InChi Code: InChI=1S/C12H25N3O2.2ClH/c1-3-10(2)11(13)12(16)14-4-5-15-6-8-17-9-7-15;;/h10-11H,3-9,13H2,1-2H3,(H,14,16);2*1H/t10-,11-;;/m0../s1


Solid powder

>96% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Soluble in DMSO 100.0

Preparing Stock Solutions

The following data is based on the product molecular weight 316.267 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). Do not reply directly to this message

Sent On: Fri Oct 23 09:51:42 2020

Search: LM11A-31

20 selected items

PubMed Results
Items 1-20 of 20 (Display the 20 citations in PubMed)

1: Xie Y, Seawell J, Boesch E, Allen L, Suchy A, Longo FM, Meeker RB. Small molecule modulation of the p75 neurotrophin receptor suppresses age- and genotype-associated neurodegeneration in HIV gp120 transgenic mice. Exp Neurol. 2020 Sep 29;335:113489. doi: 10.1016/j.expneurol.2020.113489. Epub ahead of print. PMID: 33007293.

2: Yang T, Liu H, Tran KC, Leng A, Massa SM, Longo FM. Small-molecule modulation of the p75 neurotrophin receptor inhibits a wide range of tau molecular pathologies and their sequelae in P301S tauopathy mice. Acta Neuropathol Commun. 2020 Sep 5;8(1):156. doi: 10.1186/s40478-020-01034-0. PMID: 32891185; PMCID: PMC7487850.

3: McGregor C, Sabatier M, English A. Early regeneration of axons following peripheral nerve injury is enhanced if p75NTR is eliminated from the surrounding pathway. Eur J Neurosci. 2020 Aug 19. doi: 10.1111/ejn.14943. Epub ahead of print. PMID: 32812660.

4: Foerster Y, Stöver T, Wagenblast J, Diensthuber M, Balster S, Gabrielpillai J, Petzold H, Geissler C. Relevance of Neurotrophin Receptors CD271 and TrkC for Prognosis, Migration, and Proliferation in Head and Neck Squamous Cell Carcinoma. Cells. 2019 Sep 28;8(10):1167. doi: 10.3390/cells8101167. PMID: 31569361; PMCID: PMC6830344.

5: Elshaer SL, Alwhaibi A, Mohamed R, Lemtalsi T, Coucha M, Longo FM, El-Remessy AB. Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway. Diabetologia. 2019 Aug;62(8):1488-1500. doi: 10.1007/s00125-019-4885-2. Epub 2019 May 9. PMID: 31073629.

6: Xie Y, Meeker RB, Massa SM, Longo FM. Modulation of the p75 neurotrophin receptor suppresses age-related basal forebrain cholinergic neuron degeneration. Sci Rep. 2019 Mar 27;9(1):5273. doi: 10.1038/s41598-019-41654-8. PMID: 30918278; PMCID: PMC6437186.

7: Simmons DA, James ML, Belichenko NP, Semaan S, Condon C, Kuan J, Shuhendler AJ, Miao Z, Chin FT, Longo FM. TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31. Hum Mol Genet. 2018 Aug 15;27(16):2893-2912. doi: 10.1093/hmg/ddy202. PMID: 29860333; PMCID: PMC6077813.

8: Zabbarova IV, Ikeda Y, Carder EJ, Wipf P, Wolf-Johnston AS, Birder LA, Yoshimura N, Getchell SE, Almansoori K, Tyagi P, Fry CH, Drake MJ, Kanai AJ. Targeting p75 neurotrophin receptors ameliorates spinal cord injury-induced detrusor sphincter dyssynergia in mice. Neurourol Urodyn. 2018 Nov;37(8):2452-2461. doi: 10.1002/nau.23722. Epub 2018 May 28. PMID: 29806700; PMCID: PMC6202156.

9: Ji M, Yuan H, Yuan S, Xia J, Yang J. The p75 neurotrophin receptor might mediate sepsis-induced synaptic and cognitive impairments. Behav Brain Res. 2018 Jul 16;347:339-349. doi: 10.1016/j.bbr.2018.03.042. Epub 2018 Mar 28. PMID: 29604364.

10: Minnone G, Soligo M, Caiello I, Prencipe G, Manni L, Marafon DP, Magni- Manzoni S, Manzo A, De Benedetti F, Bracci-Laudiero L. ProNGF-p75NTR axis plays a proinflammatory role in inflamed joints: a novel pathogenic mechanism in chronic arthritis. RMD Open. 2017 Sep 12;3(2):e000441. doi: 10.1136/rmdopen-2017-000441. Erratum in: RMD Open. 2018 Jan 7;4(1):e000441corr1. Benedetti, Fabrizio De [corrected to De Benedetti, Fabrizio]. PMID: 28955492; PMCID: PMC5604749.

11: Kohn-Polster C, Bhatnagar D, Woloszyn DJ, Richtmyer M, Starke A, Springwald AH, Franz S, Schulz-Siegmund M, Kaplan HM, Kohn J, Hacker MC. Dual-Component Gelatinous Peptide/Reactive Oligomer Formulations as Conduit Material and Luminal Filler for Peripheral Nerve Regeneration. Int J Mol Sci. 2017 May 21;18(5):1104. doi: 10.3390/ijms18051104. PMID: 28531139; PMCID: PMC5455012.

12: James ML, Belichenko NP, Shuhendler AJ, Hoehne A, Andrews LE, Condon C, Nguyen TV, Reiser V, Jones P, Trigg W, Rao J, Gambhir SS, Longo FM. [18F]GE-180 PET Detects Reduced Microglia Activation After LM11A-31 Therapy in a Mouse Model of Alzheimer's Disease. Theranostics. 2017 Mar 24;7(6):1422-1436. doi: 10.7150/thno.17666. PMID: 28529627; PMCID: PMC5436503.

13: Haefeli J, Ferguson AR, Bingham D, Orr A, Won SJ, Lam TI, Shi J, Hawley S, Liu J, Swanson RA, Massa SM. A data-driven approach for evaluating multi-modal therapy in traumatic brain injury. Sci Rep. 2017 Feb 16;7:42474. doi: 10.1038/srep42474. PMID: 28205533; PMCID: PMC5311970.

14: Simmons DA, Belichenko NP, Ford EC, Semaan S, Monbureau M, Aiyaswamy S, Holman CM, Condon C, Shamloo M, Massa SM, Longo FM. A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice. Hum Mol Genet. 2016 Nov 15;25(22):4920-4938. doi: 10.1093/hmg/ddw316. PMID: 28171570; PMCID: PMC5418739.

15: Li B, Cai S, Zhao Y, He Q, Yu X, Cheng L, Zhang Y, Hu X, Ke M, Chen S, Zou M. Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT/β-catenin pathway. Oncotarget. 2016 Dec 6;7(49):81026-81048. doi: 10.18632/oncotarget.13186. PMID: 27835587; PMCID: PMC5348374.

16: Darcq E, Morisot N, Phamluong K, Warnault V, Jeanblanc J, Longo FM, Massa SM, Ron D. The Neurotrophic Factor Receptor p75 in the Rat Dorsolateral Striatum Drives Excessive Alcohol Drinking. J Neurosci. 2016 Sep 28;36(39):10116-27. doi: 10.1523/JNEUROSCI.4597-14.2016. Epub 2016 Sep 28. PMID: 27683907; PMCID: PMC5039257.

17: Park A. Alzheimer's From A New Angle. Time. 2016 Feb 22-29;187(6-7):64-8, 70. PMID: 27089679.

18: Meeker RB, Poulton W, Clary G, Schriver M, Longo FM. Novel p75 neurotrophin receptor ligand stabilizes neuronal calcium, preserves mitochondrial movement and protects against HIV associated neuropathogenesis. Exp Neurol. 2016 Jan;275 Pt 1(0 1):182-98. doi: 10.1016/j.expneurol.2015.09.012. Epub 2015 Sep 28. PMID: 26424436; PMCID: PMC4688079.

19: Friesland A, Weng Z, Duenas M, Massa SM, Longo FM, Lu Q. Amelioration of cisplatin-induced experimental peripheral neuropathy by a small molecule targeting p75 NTR. Neurotoxicology. 2014 Dec;45:81-90. doi: 10.1016/j.neuro.2014.09.005. Epub 2014 Sep 30. PMID: 25277379; PMCID: PMC4268328.

20: Simmons DA, Knowles JK, Belichenko NP, Banerjee G, Finkle C, Massa SM, Longo FM. A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression. PLoS One. 2014 Aug 25;9(8):e102136. doi: 10.1371/journal.pone.0102136. PMID: 25153701; PMCID: PMC4143160.

Additional Information

Breakdown of the inner blood-retinal barrier (BRB) is an early event in the pathogenesis of diabetic macular oedema, that eventually leads to vision loss.